J. Craig Venter Dies at 79
J. Craig Venter, who helped decode the human genome, has died at age 79. The FDA appointed an acting head for its biologics center and approved a new Alzheimer's drug. A biotech entrepreneur is launching an effort to scale bespoke medicines.
White House photographer / Wikimedia (Public domain)J. Craig Venter, a scientist known for decoding the human genome, died at 79. He introduced speed and competition to genomics research. Multiple sources reported his passing and reflected on his contributions to biotechnology. The New York Times described Venter as a risk-taking outsider who brought controversy to one of science's biggest races.
The agency continues to search for a permanent leader. This follows the departure of Vinay Prasad's acting replacement context mentioned in reports. The approval was announced in biotech newsletters.
Vitarello is starting a new effort to scale bespoke medicines. This comes after her first startup faced challenges. Her daughter received a bespoke medicine previously. Matt Herper reflected on Venter's legacy, noting his vision shaped modern biotech.
Venter's work in genomics pioneered advancements in the field. Sources highlighted his relentless approach and impact on biotechnology. STAT reported on his contributions in a memorial piece.
“Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood.”
Other biotech news included a five-way obesity drug showing effectiveness in mice. Akeso's survival data was discussed in a scorecard. The developments occur amid ongoing biotech innovations. Sources covered politics and research driving the industry. STAT's newsletter summarized these events for subscribers. The coverage emphasized science, politics, and money in biotech.
Key Facts
Story Timeline
4 events- May 1, 2026
STAT reported on FDA naming Katherine Szarama acting head of CBER and other biotech news.
1 sourceSTAT - April 30, 2026
Matt Herper reflected on J. Craig Venter's legacy in a STAT piece.
1 sourceSTAT - April 30, 2026
STAT covered Katherine Szarama named acting director of FDA’s vaccines and biologics center.
1 sourceSTAT - Recent
J. Craig Venter died at 79, as reported by The New York Times.
2 sourcesNYT · STAT
Potential Impact
- 01
Genomics research advances will build on Venter's foundational work.
- 02
Biotech firms will pursue more FDA approvals for specialized drugs.
- 03
Bespoke medicine initiatives will expand access to personalized treatments.
- 04
FDA's biologics center will maintain operations under acting leadership.
- 05
Obesity drug development will accelerate based on mouse study results.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…